Clinical Trial of the Week: Treatment trial for men with localized intermediate-risk prostate cancer


By Donna Loyle, communications specialist, LIMR


June is Men’s Health Month, which makes this an ideal time to highlight clinical study #NRG GU005, a randomized phase III trial comparing stereotactic body radiation therapy (SBRT) to intensity-modulated radiation therapy (IMRT) in men with stage IIA-B prostate cancer.


The study seeks to determine if SBRT is superior to IMRT in terms of genitourinary and gastrointestinal toxicity. There are two study arms: One undergoes IMRT once daily over less than 32 business days. The other undergoes SBRT at least every other day over less than 12 business days. Patients then undergo follow-up care for two years.


Study #NRG GU005 approved for Lankenau Medical Center. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email or visit

This entry was posted in Clinician News and tagged . Bookmark the permalink.

Leave a Reply

Your email address will not be published.